{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.9","value":"4.0"},{"groupId":"OG001","spread":"4.2","value":"1.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"description":"A composite bleeding episode was defined as clinically significant bleeding events or the use of a rescue medication to prevent a clinical significant bleeding event during weeks 2 through 25 of the treatment period. A clinically significant bleeding event was defined as a Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 grade ≥ 2 bleeding event.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received weekly subcutaneous placebo for 24 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants received once weekly subcutaneous romiplostim for 24 weeks at a starting dose of 1 µg/kg; weekly dose increases continued in increments of 1 µg/kg/week to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\\^9/L.","id":"OG001","title":"Romiplostim"}],"paramType":"MEAN","populationDescription":"Efficacy analysis set","reportingStatus":"POSTED","timeFrame":"Week 2 to week 25","title":"Total Number of Composite Bleeding Episodes","type":"SECONDARY","unitOfMeasure":"bleeding episodes"}